As the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus spreads around the world, it has become clear that the virus infects multiple organs, including the brain. Several clinical studies have revealed that COVID-19 infection causes a variety of neurological symptoms ranging in severity from headaches to life-threatening strokes. Although the precise mechanism by which the SARS-CoV-2 virus directly impacts the brain is unknown, several theories have been proposed, including direct and indirect virus-induced pathways. One possible theory is that SARS-CoV-2 enters the brain via the bloodstream or the nerve endings, which is thought to be the direct route. These findings are based on studies that found viral. Nonetheless, indirect mechanisms such as blood-clotting abnormalities and prolonged immune system activation can result in additional tissue and organ damage seen during the course of the disease. This overview aims to provide a comprehensive understanding of SARS-CoV-2 coronavirus neurological infection and to highlight the possible mechanisms underlying the neurological manifestations observed in infected patients. In 2020, 22% of pediatric hospitalized patients at 52 American sites had neurologic involvement in multisystem inflammatory syndrome in children (MIS-C) or severe acute coronavirus disease 2019 (COVID-19), with 12% having serious sequelae. In June 2021, the SARS-CoV-2 Delta (B.1.617.2) variant became prevalent, leading to an increase in pediatric hospitalizations in the United States. Children would be eligible for COVID-19 vaccines by 2021. The current study assessed the degree of SARS-CoV-2-related neurologic involvement and reported hospital outcomes in American adolescents and children in 2021, taking into account their status Researchers described the extent of neurologic involvement caused by SARS-CoV-2 in children and adolescents in this study. The team actively monitored nearly 55 hospitals in 31 states to identify American patients over the age of 21 who were SARS-CoV-2-infected or who met the Centers for Disease Control and Prevention (CDC) criteria for children hospitalized with MIS-C between 15 December 2020 and 31 December 2021 with acute COVID-19 symptoms and a positive SARS-CoV-2 reverse transcription-pox test. Patients with MIS-C had either a positive SARS-CoV-2 respiratory or antibody test. Qualified personnel extracted the necessary information from medical data. With a median age of 10.3 years, 58% of the 2,168 patients were male. 34% of those tested positive for acute COVID-19, while 66% tested positive for MIS-C. Patients who had neurologic involvement were older and had more underlying neurologic illnesses. Seizures were more common in younger children, while loss of smell and taste was more common in adolescents. Almost 91% of patients with neurologic involvement had non-life threatening neurological symptoms, the most common of which were headache, disorientation, weakness, and loss of taste or smell. Furthermore, 90% of patients with non-fatal neurologic involvement survived without neurological impairment, 5% died, and 4% were discharged alive while still suffering from neurologic deficits as a result of their severe illness's sequelae. 42 people out of 476 with neurologic involvement had life-threatening neurologic symptoms, including 23 with acute central nervous system (CNS) infection or acute disseminated encephalomyelitis (ADEM). Neurologic conditions with a high risk of death were seen more frequently during the Delta wave of infections than during the pre-Delta phases. Ten of the 42 patients had new neurologic impairments at discharge, and eight died as a result of the disorders. There were five confirmed cases of encephalitis and nine probable cases. The electroencephalogram revealed abnormalities such as diffuse background slowing, localized seizures, or epileptic discharges. The majority of brain MRI results showed ADEM-like characteristics, such as multifocal, non-enhancing lesions with T2 prolongation and reduced diffusivity, primarily in the deep periventricular and juxta cortical white matter. One patient's MRI revealed a low titer-positive for myelin oligodendrocyte glycoprotein antibody, as well as involvement of the left temporal lobe, which improved on a nine-month follow-up MRI. Seven of the 23 patients who were diagnosed with acute CNS infection/ADEM died. Of the 155 patients who were vaccine-eligible and had neurologic involvement with a confirmed COVID-19 vaccination status, 147 were not COVID-19-vaccinated, including 15 of 16 patients with life-threatening neurologic disorders. Overall, the study findings revealed that SARS-CoV-2-related neurologic dysfunction persisted but was mostly transient in children and adolescents hospitalized for MIS-C or COVID-19. Life-threatening disorders were more likely to involve CNS infection or demyelination, whereas the majority of patients who were eligible for the COVID-19 vaccine did not.